Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2020-03-09 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
2020年第二次临时股东大会的律师见证法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2020 second extraordinary general meeting (EGM) of shareholders of Rui Kang Pharmaceutical Group Co., Ltd. It details the legal verification of the meeting's convening, attendance, agenda, voting procedures, and results. The document does not contain financial statements or performance data but focuses on the legality and validity of the shareholder meeting and its resolutions. This type of document is typically classified as a Declaration of Voting Results & Voting Rights Announcement (DVA), as it officially reports the voting outcomes and related legal opinions on the shareholder meeting.
2020-03-09 Chinese
2020年第二次临时股东大会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as an announcement of the resolutions from the 2020 second extraordinary general meeting of shareholders of Ruikang Pharmaceutical Group Co., Ltd. It details the meeting notice, attendance, voting results on various proposals, and legal witness statements. The content focuses on the official results of shareholder votes at a general meeting, including vote counts and approval status of proposals. There is no financial data, no presentation materials, no management discussion, nor is it a report or announcement of a report publication. The document fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and it is an announcement of voting results, not a full report or other filing type.
2020-03-09 Chinese
关于对深圳证券交易所关注函的回复
Audit Report / Information Classification · 95% confidence The document is a detailed reply from 瑞康医药集团股份有限公司 to a regulatory inquiry from the Shenzhen Stock Exchange regarding goodwill impairment and related accounting treatments. It includes extensive financial data, impairment testing explanations, accounting policy references, and detailed tables of goodwill amounts and impairment calculations. The content focuses on accounting principles, impairment testing, and financial disclosures related to goodwill and derivative financial liabilities. There is no indication that this is a full annual report or interim report, nor is it a brief announcement or a certification letter. The document is a standalone audit-related disclosure addressing regulatory concerns about accounting treatments and impairment testing, which fits the category of an Audit Report / Information filing rather than a full Annual Report or other categories. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2019
2020-03-02 Chinese
2020年第一次临时股东大会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2020 first extraordinary general meeting (临时股东大会) of 瑞康医药集团股份有限公司. It details the meeting's convocation, attendance, voting results on various proposals including guarantees and issuance of short-term financing bonds, and legal opinion on the meeting's validity. The document is not a full report but an official announcement of voting results from a shareholders' meeting. It does not contain financial statements or detailed financial analysis. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3287 characters, which is relatively short and consistent with an announcement rather than a full report.
2020-02-27 Chinese
2020年第一次临时股东大会的律师见证法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of a company's 2020 first extraordinary general meeting (临时股东大会). It details the verification of the meeting's legality, the qualifications of attendees, the agenda items, and the voting outcomes. The document is not a financial report, earnings release, or management discussion, but rather a legal certification of the shareholder meeting and its resolutions. This type of document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and validates the shareholder meeting proceedings.
2020-02-27 Chinese
联合信用评级有限公司关于公司2019年年度业绩快报的关注公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1093 characters) from a credit rating agency about the company's 2019 annual performance quick report. It references the company's 2019 annual performance data but does not contain the full annual report itself. The document discusses credit rating concerns and financial highlights but is primarily an announcement regarding the company's credit rating and performance update. It does not contain full financial statements or detailed analysis typical of an Annual Report (10-K). Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS) rather than the full Annual Report or Earnings Release.
2020-02-26 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.